Skip to main content
OpenTrials
Completed

NCT Number: NCT03331900

Study of COR388 HCl in Healthy Subjects

The study is a randomized, double-blind, placebo-controlled, dose escalation, first-in-human trial of the safety and tolerability of COR388 HCl in healthy male and female subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Medpace Clinical Pharmacology Unit

Cincinnati, Ohio, 45227, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Major Inclusion Criteria:

  • Males of reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse from Day -1 through 28 days after the dose of study drug;
  • Females of child-bearing potential must be non-lactating, have negative serum pregnancy test results at screening visit and Day 1; agree to use double-barrier contraceptive measures or avoid intercourse from Day -10 through 28 days after the dose of study drug;
  • Body mass index (BMI) ≥19 to ≤32 kg/m2;
  • Good health as determined by the absence of clinically significant deviation from normal, by medical history, physical examination, laboratory reports, and 12-lead electrocardiogram (ECG) prior to enrollment;
  • Non-smoker and non-tobacco user for a minimum of 3 months prior to screening and for the duration of the study;
  • Able to understand and willing to comply with all study requirements, and follow the study medication regimen.

Major Exclusion Criteria:

  • History or current evidence of cardiac, hepatic, renal, pulmonary, endocrine, neurologic, gastrointestinal, hematologic, oncologic, infectious, or psychiatric disease as determined by screening history, physical examination, laboratory reports, or 12-lead ECG;
  • Need for any concomitant medication (with the exception of hormonal contraceptives as allowed for females of child-bearing potential);
  • Use of any prescription drug within 14 days prior to the first dose of the study (with the exception of hormonal contraceptives for females of childbearing potential);
  • Use of any non-prescription drug and/or herbal supplements within 7 days prior to the first dose of the study;
  • History of significant allergic reaction to any drug;
  • Participation in another investigational new drug research study within the 30 days prior to the first dose of the study;
  • History of alcohol or drug abuse or dependence within 12 months of screening as determined by the Investigator;
  • Positive urine screen for prohibited drugs or positive alcohol screen on Day -1.

Treatment and study plan

COR388

Drug

Administered as oral capsule

Placebo

Drug

Administered as oral capsule

Primary outcomes

  1. Area under the plasma concentration curve (AUC)

    Time frame: 72 hours

    Analysis of AUC

  2. Maximum observed plasma concentration (Cmax)

    Time frame: 72 hours

    Analysis of Cmax

  3. Time of the first occurrence of the maximum observed plasma concentration (Tmax)

    Time frame: 72 hours

    Analysis of Tmax

Secondary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: 72 Hours

    Assessment of the incidence and severity of treatment-emergent adverse events.

  2. Changes in chemistry lab measures (Sodium [Na], Blood Urea Nitrogen [BUN], Calcium [Ca], Total bilirubin).

    Time frame: 72 hours

    Assessment of changes in serum chemistry measures.

  3. Changes in hematology lab measures (RBC, Hgb, Hct).

    Time frame: 72 hours

    Assessment of changes in hematology measures.

  4. Changes in urinalysis lab parameters (pH, specific gravity, glucose).

    Time frame: 72 hours

    Assessment of changes in urinalysis parameters.

Sponsors and collaborators

Lead sponsor

Cortexyme Inc.

Industry

Registry information

Official study title

A Phase 1 Single Ascending Dose Study of COR388 HCl

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Nov 6, 2017
Registry last updated
Apr 18, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.